TY - JOUR
T1 - Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival
AU - Venkataraman, Girish
AU - Song, Joo Y.
AU - Tzankov, Alexandar
AU - Dirnhofer, Stephan
AU - Heinze, Georg
AU - Kohl, Maria
AU - Traverse-Glehen, Alexandra
AU - Eberle, Franziska C.
AU - Hanson, Jeffrey C.
AU - Raffeld, Mark A.
AU - Pittaluga, Stefania
AU - Jaffe, Elaine S.
PY - 2013/3/7
Y1 - 2013/3/7
N2 - Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) rarely express T-cell-associated antigens (TCA), but the clinical significance of this finding is uncertain. Fifty cHLs expressing any TCA on the HRS cells (TCA-cHL) were identified in two cohorts (National Cancer Institute, n 5 38; Basel, n 5 12). Diagnostic pathology data were examined in all cases with additional T-cell receptor g rearrangements (TRG) polymerase chain reaction (PCR) in a subset of cases. The outcome data were compared with a cohort of cHLs negative for TCA (n 5 272). Primary end points examined were event-free survival (EFS) and overall survival (OS). The median age in the TCA-cHL group was 40 years (range, 10-85 years). Seventy percent presented in low stage (stage I/II) at presentation with nodular sclerosis (NS) histology predominating in 80% of cases. Among the TCA, CD4 and CD2 were most commonly expressed, seen in 80.4% and 77.4% of cases, respectively. TRG PCR was negative for clonal rearrangements in 29 of 31 cases. During a median follow up of 113 months, TCA expression predicted shorter OS (adjusted hazard ratio [HRadj] 5 3.32 [95% confidence interval (CI): 1.61, 6.84]; P 5 .001) and EFS (HRadj 5 2.55 [95% CI: 1.45, 4.49]; P 5 .001). TCA-cHL often display NS histology, lack T-cell genotype, and are independently associated with significantly shorter OS and EFS compared with TCA-negative cHLs.
AB - Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) rarely express T-cell-associated antigens (TCA), but the clinical significance of this finding is uncertain. Fifty cHLs expressing any TCA on the HRS cells (TCA-cHL) were identified in two cohorts (National Cancer Institute, n 5 38; Basel, n 5 12). Diagnostic pathology data were examined in all cases with additional T-cell receptor g rearrangements (TRG) polymerase chain reaction (PCR) in a subset of cases. The outcome data were compared with a cohort of cHLs negative for TCA (n 5 272). Primary end points examined were event-free survival (EFS) and overall survival (OS). The median age in the TCA-cHL group was 40 years (range, 10-85 years). Seventy percent presented in low stage (stage I/II) at presentation with nodular sclerosis (NS) histology predominating in 80% of cases. Among the TCA, CD4 and CD2 were most commonly expressed, seen in 80.4% and 77.4% of cases, respectively. TRG PCR was negative for clonal rearrangements in 29 of 31 cases. During a median follow up of 113 months, TCA expression predicted shorter OS (adjusted hazard ratio [HRadj] 5 3.32 [95% confidence interval (CI): 1.61, 6.84]; P 5 .001) and EFS (HRadj 5 2.55 [95% CI: 1.45, 4.49]; P 5 .001). TCA-cHL often display NS histology, lack T-cell genotype, and are independently associated with significantly shorter OS and EFS compared with TCA-negative cHLs.
UR - http://www.scopus.com/inward/record.url?scp=84876534485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876534485&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-06-439455
DO - 10.1182/blood-2012-06-439455
M3 - Article
C2 - 23305738
AN - SCOPUS:84876534485
VL - 121
SP - 1795
EP - 1804
JO - Blood
JF - Blood
SN - 0006-4971
IS - 10
ER -